Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open- label, phase II trial

Chesney, Jason A.; Puzanov, Igor; Collichio, Frances A.; Singh, Parminder; Milhem, Mohammed M.; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbe, Celeste; Joshi, Harshada; Snyder, Wendy; Mehnert, Janice M.

dc.contributor.author	Garbe, Claus
dc.date.accessioned	2023-07-17T07:49:14Z
dc.date.available	2023-07-17T07:49:14Z
dc.date.issued	2023
dc.identifier.issn	2051-1426
dc.identifier.uri	http://hdl.handle.net/10900/143482
dc.language.iso	en	de_DE
dc.publisher	Bmj Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1136/jitc-2022-006270	de_DE
dc.subject.ddc	570	de_DE
dc.subject.ddc	610	de_DE
dc.title	Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open- label, phase II trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20230619000000_00239
utue.personen.roh	Chesney, Jason A.
utue.personen.roh	Puzanov, Igor
utue.personen.roh	Collichio, Frances A.
utue.personen.roh	Singh, Parminder
utue.personen.roh	Milhem, Mohammed M.
utue.personen.roh	Glaspy, John
utue.personen.roh	Hamid, Omid
utue.personen.roh	Ross, Merrick
utue.personen.roh	Friedlander, Philip
utue.personen.roh	Garbe, Claus
utue.personen.roh	Logan, Theodore
utue.personen.roh	Hauschild, Axel
utue.personen.roh	Lebbe, Celeste
utue.personen.roh	Joshi, Harshada
utue.personen.roh	Snyder, Wendy
utue.personen.roh	Mehnert, Janice M.
dcterms.isPartOf.ZSTitelID	Journal For Immunotherapy of Cancer	de_DE
dcterms.isPartOf.ZS-Issue	Article e006270	de_DE
dcterms.isPartOf.ZS-Volume	11 (5)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE